AG真人官方

Schedule 13G Filing 鈥� INmune Bio Inc. (NASDAQ: INMB)

CVI Investments, Inc. and its investment manager Heights Capital Management, Inc. have disclosed passive ownership of 1,500,000 common shares of INmune Bio Inc., representing 5.5 % of the company鈥檚 27.24 million shares outstanding as of the June 30 2025 prospectus supplement. The reporting persons claim shared voting and dispositive power over all 1.5 million shares; neither holds sole authority. Both entities certify the stake was not acquired to influence control of the issuer.

The filing date of event is 27 June 2025, triggering disclosure because ownership crossed the 5 % threshold. CVI is a Cayman-domiciled fund, while Heights Capital (Delaware) acts as investment manager and authorized agent, as evidenced by a limited power of attorney (Exhibit I). Sarah Travis signed on behalf of both entities on 2 July 2025.

Because the form is a 13G (rather than 13D), the investors are declaring a passive stake; there is no stated intent to seek board representation, propose strategic changes, or otherwise influence management. Nevertheless, the presence of a professional investment manager holding more than 5 % can affect trading liquidity, perception of institutional support, and future ownership dynamics.

Netcapital Inc. (Nasdaq: NCPL) filed an 8-K reporting that on 26 June 2025 it entered into a Horizon Software Agreement with Switzerland-based Horizon Globex GmbH. Horizon granted Netcapital a royalty-free, paid-up, non-exclusive, perpetual and irrevocable license to use Horizon鈥檚 capital-raising and secondary-trading software under the Company鈥檚 own branding in the United States.

As consideration, Netcapital will issue 500,0000 shares of its common stock (the 鈥淗orizon Shares鈥�) to Horizon or its affiliate. The shares will be issued without registration under Sections 4(a)(2) and/or 3(a)(9) of the Securities Act, and no cash will be received by the Company.

The agreement includes standard termination rights: (i) either party may terminate after a 30-day cure period for material breach, and (ii) immediate termination is permitted upon bankruptcy, receivership, dissolution, or cessation of business of the other party. The full contract is attached as Exhibit 10.1.

This transaction gives Netcapital long-term access to a trading technology platform that could expand its service offering, but it also introduces equity dilution and execution risk should the software fail to drive revenue growth.

Chipotle Mexican Grill, Inc. (CMG) 鈥� Form 4 insider transaction

On 06/25/2025, Curtis E. Garner, Chipotle鈥檚 President, Chief Strategy & Technology Officer, reported the sale of 63,000 shares of common stock. The transaction was executed at a weighted-average price of $55.1402 per share, with actual sales prices ranging from $55.00 to $55.31. Following the sale, Garner鈥檚 direct beneficial ownership stands at 355,482 CMG shares.

The filing indicates a 鈥淪鈥� (sale) transaction code and does not reference any derivative security activity. No Rule 10b5-1 trading plan box was checked, suggesting the trade was made outside a pre-arranged plan. The report was signed on 06/30/2025 by attorney-in-fact Helen Kaminski.

• Reporting person: Curtis E. Garner (Officer 鈥� President, Chief Strategy & Technology Officer)
• Shares sold: 63,000
• Average price: $55.1402 (range $55.00 鈥� $55.31)
• Shares remaining: 355,482 (direct ownership)
• Form filed individually, not jointly

Investors typically watch insider sales closely, as they can signal executive sentiment or liquidity needs. However, the form does not disclose the percentage of total ownership sold, any specific rationale for the sale, or whether the trade was made under a pre-existing plan, limiting definitive interpretation of motive or materiality.

On June 30, 2025 INmune Bio, Inc. (NASDAQ: INMB) filed a Form 8-K under Item 8.01 to report a material corporate event. The company issued a press release disclosing topline results from its Phase 2 MINDFuL trial of XPro鈩� in patients with early Alzheimer鈥檚 disease. The 8-K itself does not include numerical efficacy or safety data but incorporates the press release (Exhibit 99.1) and an updated corporate presentation (Exhibit 99.2) by reference, directing investors to those documents for detailed findings and development strategy.

The disclosure marks a critical clinical milestone for INmune Bio because XPro is its lead asset in a large, high-value neuro-degenerative market. While the filing confirms trial completion and data availability, the absence of quantitative outcomes prevents immediate assessment of clinical success, regulatory pathway, or commercial outlook. Investors will need to review the accompanying exhibits鈥攐r await further commentary from management鈥攖o evaluate next-step implications such as Phase 3 design, partnership interest, or funding requirements.

No financial statements, earnings figures, or transactional details accompanied the filing. The company left all boxes related to Rule 425, proxy solicitation, and tender-offer communications unchecked, indicating that the 8-K is confined to the scientific update. Overall, the event is potentially material but its impact鈥攑ositive or negative鈥攔emains indeterminate until the underlying data are scrutinised.

INmune Bio (NASDAQ:INMB) filed an 8-K announcing it will host a conference call on June 30, 2025 at 8:00 a.m. ET to present top-line data from its Phase 2 MINDFuL trial in early Alzheimer鈥檚 disease.

The filing:

• Attaches the related press release as Exhibit 99.1
• Provides no efficacy or safety figures; full results will be disclosed during the call
• Contains no changes to financial statements or guidance

The scheduling of a data read-out signals analysis completion and sets a near-term catalyst for shareholders, but the document itself does not alter the company鈥檚 financial position.